Screened 2026-09-08 · the tape above runs as of 00:54 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Salesforce holds its Markup at $249.12. Consolidating, no directional conviction, held for 11 days.
As held on the ledger · 2026-09-08
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 11 days
Price at the screen
$249.12
Valuation
22.83 trailing · 15.56 forward price to earnings
Values screen
PASS· score 86.8
Beta
1.20
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
15.29%
Below 33%
Interest-bearing debt is just 15.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.72%
Below 33%
Cash held in interest-bearing accounts and securities is 6.7% of assets, under the one-third limit.
Pass
Receivables
19.29%
Below 49%
Money owed to the company is 19.3% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 36% discount to our $338.12 fair value, moderate competitive moat, 10.80% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 35.7% margin of safety to the base estimate.
Third-party analyst targets: 54 covering, consensus Buy. The average target sits +9% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Salesforce Bridges the Customer Gap
Imagine a world where every interaction between customers and companies is smooth and intuitive, that's Salesforce's vision. It's the tech that powers the conversation, allowing businesses to understand and serve their customers better. Why it stands out is the blend of strong revenue growth at 13% and a healthy profit margin of 19%, which provides a sturdy foundation for its future prospects. The company's forward P/E of 13.2x is a steal compared to our fair value of $291.25, signaling an opportunity with a margin of safety of +42%.
Yet, every opportunity comes with its share of risks. The moderate moat suggests that while Salesforce has a competitive advantage, it's not unassailable. The technology sector is fast-paced, with new entrants and disruptors a constant threat. Additionally, with 52 analysts giving a consensus buy rating and a median target of $233, there's a general optimism, but also the potential for overvaluation if growth expectations aren't met.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-26Markup$205.43+0.0%Entry 12
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$205.43+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Markup$205.43+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$205.43+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Markup$205.43+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Markup$205.43+6.5%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-20Markup$192.98+0.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-19Markup$192.98+17.9%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 17.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Markup$163.66-11.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 11.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262.
2026-07-18Markup$185.66+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
